A validated HPLC‐MS/MS method for determination of simmitecan and its metabolite chimmitecan in human plasma and its application to a pharmacokinetic study in Chinese patients with advanced solid tumor

Author(s):  
Jun Zhou ◽  
Yan Zhan ◽  
Dafang Zhong ◽  
Xiaoyan Chen ◽  
Yifan Zhang ◽  
...  
Bioanalysis ◽  
2019 ◽  
Vol 11 (16) ◽  
pp. 1483-1493
Author(s):  
Yu Li ◽  
Qian Zhao ◽  
Pei Hu ◽  
Ji Jiang

Aim: CX1003 is a novel multitargeted receptor tyrosine kinase inhibitor targeting cancer patients with relapsed or metastatic malignant solid tumors. The study aimed to develop a robust and rapid assay approach to quantify CX1003 in human plasma. Methodology & results: Samples of plasma were purified by SPE where the diluted eluates were then separated by a Waters Acquity CSH C18 column and thereafter detected using positive electrospray ionization via an ultra performance LC–MS/MS. Conclusion: The method to quantify CX1003 in human plasma was first exploited and validated with good sensitivity and specificity, and successfully fulfilled the requirement of the first-in-human clinical pharmacokinetic study of CX1003 in Chinese patients with relapsed or metastatic malignant solid tumors.


Bioanalysis ◽  
2014 ◽  
Vol 6 (18) ◽  
pp. 2343-2356 ◽  
Author(s):  
Jiangbo Du ◽  
Zhiyu Ma ◽  
Yifan Zhang ◽  
Ting Wang ◽  
Xiaoyan Chen ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document